For Patients

PeptiCRAd-1 for treatment of melanoma, triple-negative breast cancer, non-small cell lung cancer or sarcoma

The clinical trial "VALO-001" is open for recruitment in Germany

 

PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus 1) in combination with immune checkpoint inhibitor (CPI), pembrolizumab in patients with melanoma, triple-negative breast cancer or non-small cell lung cancer

 

IF YOU ARE INTERESTED TO PARTICIPATE AS A STUDY PATIENT

Please contact:

Krankenhaus Nordwest, Klinik für Hämatologie und Onkologie, Steinbacher Hohl 2-26, 60488 Frankfurt am Main

Tel.: 069 / 7601 1

or

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg

Tel.: 06221 / 56 5615

or

 Universitätsklinikum Tübingen, Otfried-Müller-Str. 10 72076 Tübingen

Tel.: 07071 / 29-82712

The study physician will evaluate if you may be a suitable candidate for the study. For example, participants must have a certain stage of disease, health status, and be eligible for treatment with pembrolizumab in order to be included in the study. The physician at the study site can evaluate your eligibility based on the inclusion and exclusion criteria for the study.

Clinical trial registry: https://www.clinicaltrials.gov/ct2/show/NCT05492682